Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Prescient Therapeutics Limited ( (AU:PTX) ) has shared an update.
Prescient Therapeutics Limited has announced a share purchase plan (SPP) aimed at raising up to $7 million, allowing eligible shareholders to purchase shares at $0.04 each. This capital raising initiative is part of the company’s strategy to advance its clinical programs, including the development of PTX-100 and its cell therapy platforms, potentially strengthening its position in the oncology market and offering promising implications for stakeholders.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches for cancer treatment. Their primary products include targeted therapies like PTX-100, a unique GGT-1 inhibitor, and cell therapy platforms such as CellPryme-M, CellPryme-A, and OmniCAR, which enhance the effectiveness of adoptive cell therapies and CAR-T cell treatments.
Average Trading Volume: 903,701
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$37.04M
For detailed information about PTX stock, go to TipRanks’ Stock Analysis page.